SBIR Phase II:Sensitive, Rapid Heterogeneous Immunoassays Based on Surface Enhanced Raman Scattering and Gold Nanoparticle Labels

Award Information
Agency:
National Science Foundation
Amount:
$381,132.00
Program:
SBIR
Contract:
1026890
Solitcitation Year:
2010
Solicitation Number:
NSF 08-548
Branch:
N/A
Award Year:
2010
Phase:
Phase II
Agency Tracking Number:
0839773
Solicitation Topic Code:
BC
Small Business Information
Concana
150 Hamakua Dr. PMB 702, Kailua, HI, 96734
Hubzone Owned:
N
Woman Owned:
N
Socially and Economically Disadvantaged:
N
Duns:
130275428
Principal Investigator
 Christian Schoen
 (808) 263-6387
 cschoen@concana.com
Business Contact
 Christian Schoen
Phone: (808) 263-6387
Email: cschoen@concana.com
Research Institution
N/A
Abstract
This Small Business Innovation Research (SBIR) Phase II project continues the development of an innovative diagnostic technology based on surface-enhanced Raman scattering (SERS) through its combination with gold nanoparticle labels, high-speed fluid handling, and sandwich-based immunoassays. This project, which builds on the successes of the SBIR Phase I effort, reflects a clear market need for high-speed, low-cost testing capable of providing rapid results commensurate with clinical diagnostic demands. As a market-entry point, the overarching goal is to create an extensible, multiplexed diagnostics platform for the causative agents of herpes: herpes simplex virus type 1 and type 2 (HSV-1 and HSV-2). Herpes has reached near pandemic levels in the United States and other countries around the world. The development of such a detection platform would have clear utility across the diagnostics marketplace, from the physician's office and in-hospital POC to third-party clinical diagnostic laboratories, as a multiplexed platform for sexually transmitted diseases and beyond. The broader impacts of this research are realized with the development of a technique capable of providing absolute quantitation of HSV and many other viral diseases. Such a diagnostic tool would find a niche in large clinical laboratories, in research laboratories evaluating the antiviral efficacy of candidate vaccines, and with pathologists for defining infective pathogen thresholds, setting the stage for this technology to emerge as one of the premier tools in an arsenal of diagnostic technologies.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government